VAKA DOSYASI Kaynaklar 1. Stahl SM, Mood Disorders, in Stahl’s Essential Psycnopharmacofogy, 3rd edltion, Cambridge University Press, New York, 2008, pp 453-510 2. Stahl SM, Antidepressants, in Stahl’s Essential Psychopharmacology, 3rd edition, Cambridge University Press, New York, 2008, pp 511-666 3. Stahl SM, Mirtazapine, in Stahl’s Essential Psychopharmacology The Prescriber’s Guide, 3rd edition, Cambridge University Press, New York, 2009, pp 347-51 4. Stahl SM, Venlafaxine, in Stahl’s Essential Psychopharmacology The Prescriber’s Guide, 3rd edition, Cambridge University Press, New York, 2009, pp 579-84 5. Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based çare in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40 6. Rush AJ, Trivedi MH, Wisniewski SR et al. Bupropion-SR, sertraline, or venlafaxine-XR afterfailure of SSRIs for depression. N Engl J Med 2006; 354(12): 1231-42 7. Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-17 8. Warden D, Rush AJ, Trivedi MH et al. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep 2007; 9(6): 449-59 9. Judd LL, Akiskal HS, Maser JD et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998; 50(2-3): 97-108 10. Kendler, KS, Thornton, LM, Gardner, CO. Stressful life events and previous episodes in the etiology of majör depression in women: an evaluation of the “kindling” hypothesis. Am J Psychiatry 2000; 157: 1243-51
307